HD2026 Milton Wexler Biennial Symposium

The symposium brings together the global Huntington's disease research community to share the latest scientific discoveries and explore new approaches to developing therapies.

Our CSO, Andy Billinton, will be attending. If you're there, we'd love to connect.

#HarnessTherapeutics #HuntingtonsDisease #Neuroscience #Biotech

Our programmes

Huntington's Disease

ALS and Alzheimer's

Parkinson’s Disease

Our news

June 2026

Harness Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Parkinson's Disease Programme

Read more

February 2026

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board

Read more

October 2025

Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment

Read more

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

Read more